about
Perspectives on dual hepatitis B and C infection in TaiwanMolecular mechanism and treatment of viral hepatitis-related liver fibrosis.Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysisAsian consensus on the relationship between obesity and gastrointestinal and liver diseases.Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.Milder clinical manifestation of scrub typhus in Kinmen, Taiwan.Associated factors and clinical implications of serum aminotransferase elevation in scrub typhus.Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses.Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrenceThe CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In VivoHost genetic factors affecting spontaneous HBsAg seroclearance in chronic hepatitis B patients.Circulating programmed death-1 as a marker for sustained high hepatitis B viral load and risk of hepatocellular carcinoma.Longitudinal change of HBsAg in HBeAg-negative patients with genotype B or C infection.Impact of genetic heterogeneity in polymerase of hepatitis B virus on dynamics of viral load and hepatitis B progression.Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update.Erratum to: Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update.Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibitionRapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected Patients.End-of-treatment virologic response does not predict relapse after lamivudine treatment for chronic hepatitis B.Therapeutic implications of hepatitis B virus genotypes.Epidemiology of HBV infection in Asian blood donors: emphasis on occult HBV infection and the role of NAT.Natural course and treatment of hepatitis D virus infection.Liver Gene Expression Profiles Correlate with Virus Infection and Response to Interferon Therapy in Chronic Hepatitis B PatientsCharacterization of metastatic tumor antigen 1 and its interaction with hepatitis B virus X protein in NF-κB signaling and tumor progression in a woodchuck hepatocellular carcinoma model.Updates on the treatment and outcomes of dual chronic hepatitis C and B virus infection.Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese.Global perspective on the natural history of chronic hepatitis B: role of hepatitis B virus genotypes A to J.Treatment of patients with dual hepatitis C virus and hepatitis B virus infection: resolved and unresolved issues.The clinical significance of occult hepatitis B transfusion in Taiwan--a look-back study.Consensus cost-effectiveness model for treatment of chronic hepatitis B in Asia Pacific countries.Influence of Metabolic Risk Factors on Risk of Hepatocellular Carcinoma and Liver-related Death in Men with Chronic Hepatitis B: A Large Cohort Study.Impact of occult hepatitis B on the clinical outcomes of patients with chronic hepatitis C virus infection: A 10-year follow-up.Combination Therapy for Chronic Hepatitis B: Current Updates and Perspectives.The Asia-Pacific Working Party on Nonalcoholic Fatty Liver Disease Guidelines 2017 Part 1: Definition, risk factors and assessment.Long-term Effects of Hepatitis B Immunization of Infants in Preventing Liver Cancer.Progressive accumulation of mutations in the hepatitis B virus genome and its impact on time to diagnosis of hepatocellular carcinoma.Characterization of interleukin 8 in woodchucks with chronic hepatitis B and hepatocellular carcinoma.Significance of definitions of relapse after discontinuation of oral antivirals in HBeAg-negative chronic hepatitis B.More than a virus: a qualitative study of the social implications of hepatitis B infection in China.
P50
Q26799281-05EADFE8-B082-49CD-BCEC-63CCE918E957Q27692609-31E28CC9-7251-4F50-A1D1-CC1D9461CA90Q28285945-3509F961-45EE-436A-9F21-8B98CB2E7104Q30251719-DD725B70-3662-467A-9616-FF552142B2C9Q30391932-A49C86DE-4013-49D0-8D7C-22C3461F9E48Q33365961-A9B749B6-7C3B-407F-A264-D28DEBD5FF54Q33406716-535A7A4B-1265-4374-94CA-ED0E42725659Q33419588-C0E1B76D-74FC-4FC1-9651-8D511EE1A55EQ33939443-1D332619-9BB2-450C-A582-A5A0CCF0D940Q34093919-8E51082C-203B-4ACC-BC23-7CA1F5C51826Q34459390-DBE669D8-B103-46C7-B33B-891EA48835D9Q34551114-9B30AF09-83DC-497E-995D-BCB7C6AF9848Q34576356-2E003519-375F-4B1A-A849-7EB12588370AQ34598267-B026D1A0-AD87-49AF-809B-C8DF3D278AE6Q34922094-3242FB50-C44C-4B26-B8AF-4B999910C7BEQ35706189-682E5179-61B1-4BCE-BFEA-53395F371B3EQ35706299-2CDE5705-F0F5-48BA-99B6-A3BD29C7ED68Q35740334-3A3342B4-9D74-4ED8-9C5B-9B32BEB35CB6Q35773677-0951D3BA-34B2-4FED-A191-998310A1FF61Q36180349-C69B47AA-A25B-4681-BC98-088E8DE29295Q36338675-D1286853-A691-4BCD-99D0-9E85248E6767Q36532437-F4884289-7BED-4747-9D58-EBBDCE390980Q36650967-B6225A9A-0880-416F-9243-309ADD4CFD51Q37193200-4F36AC47-9777-4DD8-9318-AFFF1F680455Q37565083-1216D4E5-38ED-40C1-BE07-C5162B58D484Q37654521-7C432238-6610-468E-8F78-36643BD55667Q38022260-5E9D0AAD-FB74-4932-857A-108050A268D5Q38113175-0390493B-A795-4A44-A8BD-625A1675FF50Q38160511-662B5C0A-E60E-458D-B181-3FD595F3C25CQ38415125-8EFF4820-038F-49A6-B3A9-E2DBD4B5441DQ38552485-9B5850D2-BBE6-4DDF-8561-E0069C823CC7Q38677390-CF7C9586-C50D-4C21-8E3A-0D8761CE8BEFQ39066741-A805D3AF-1F58-4D93-9421-95421800DB89Q39298929-87B264E1-33D4-480C-87FD-0D4E166A7D75Q39410610-FE16C7C0-A2B7-4890-9440-83E1C1976BA6Q39705211-4F6D698B-56C7-428D-9683-E9A949B3AD89Q39733935-5D6C0480-D667-4F79-9AA0-0AC8D4787A23Q39923630-2EBF9BD4-A401-4687-8CB3-B7E740530707Q40062860-6E3D394C-7C3F-4052-8C7A-8DA02F3A6E2FQ40099139-496D18D1-FDC4-4E80-9134-D746D371C52F
P50
description
onderzoeker
@nl
researcher, ORCID id # 0000-0002-6202-0993
@en
name
Chun-Jen Liu
@ast
Chun-Jen Liu
@en
Chun-Jen Liu
@es
Chun-Jen Liu
@nl
type
label
Chun-Jen Liu
@ast
Chun-Jen Liu
@en
Chun-Jen Liu
@es
Chun-Jen Liu
@nl
prefLabel
Chun-Jen Liu
@ast
Chun-Jen Liu
@en
Chun-Jen Liu
@es
Chun-Jen Liu
@nl
P106
P1153
36067524000
P31
P496
0000-0002-6202-0993